Christopher Boyer on Muck Rack

Christopher Boyer

Knoxville
As seen in: Nature, Wiley Online Library, Cambridge University Press & Assessment, BMJ Open, SAGE Publishing, Military Review, Cell Press, Health Affairs, WDIV-TV (Detroit, MI), Emerald Publishing and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christopher

Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide

|
By Hamlet Gasoyan, Rebecca J. Schulte, Christopher Boyer
| Wiley Online Library
1 Introduction Obesity represents a major public health and economic challenge, impacting 40% of US adults and is associated with a 3–11-fold increase in the risk of major health complications, such as type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea [1-5].
Open in Who Shared Issue with article?

From the cartooning pen of Christopher Boyer

|
By Christopher Boyer
| Big Pivots
Your email address will not be published. Save my name, email, and website in this browser for the next time I comment.
Open in Who Shared View Duplicates (555) Issue with article?

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study | Nature Communications

|
By Guozhang Lin, Christopher Boyer, Shi Zhao, Kehang Li, David SC Hui, Eng Kiong Yeoh
| Nature
Abstract While treatment with nirmatrelvir/ritonavir or molnupiravir is effective in lowering the rate of severe COVID-19, the effectiveness of these antivirals in reducing the risk of cardiovascular outcomes, especially among the hospitalized population, remains largely unknown. In this study, we assessed the real-world effectiveness of nirmatrelvir/ritonavir and molnupiravir on short- and long-term cardiovascular complications of COVID-19 using a target trial emulation design.
Open in Who Shared Issue with article?
See all 31 licensed articles (47 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Christopher

Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified